CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 76% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
Country • Select Country
    Entity • The products and services listed on this website are not available to US residents.
    English العَرَبِيَّة Deutsch ελληνικά Español Français Italiano Magyar Nederlands Polski Română Русский 简体中文 繁體中文

    Trade PDS Biotechnology Corporation - PDSB CFD

    5.18
    1.71%
    • Summary
    • Historical Data
    • Events
    • Income Statement
    • Balance Sheet
    • Cash Flow
    • Ownership
    Trading Conditions
    Spread 0.07
    Long position overnight fee

    Long position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee -0.026151 %
    Charges from full value of position ($-4.97)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		-0.026151%
    Short position overnight fee

    Short position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee 0.003929 %
    Charges from full value of position ($0.75)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		0.003929%
    Overnight fee time 21:00 (UTC)
    Min traded quantity 1
    Currency USD
    Margin 5%
    Stock exchange United States of America
    Commission on trade 0%

    *Information provided by Capital.com

    PDS Biotechnology Corp ESG Risk Ratings

    High Medium Low Negligible

    ‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

    More ESG coverage

    Key Stats
    Prev. Close* 5.27
    Open* 5.28
    1-Year Change* 60.98%
    Day's Range* 5.12 - 5.28
    52 wk Range 2.89-13.65
    Average Volume (10 days) 361.09K
    Average Volume (3 months) 14.04M
    Market Cap 182.74M
    P/E Ratio -100.00K
    Shares Outstanding 30.87M
    Revenue N/A
    EPS -1.61
    Dividend (Yield %) N/A
    Beta 1.92
    Next Earnings Date Nov 13, 2023

    All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

    • Last Week
    • Last Month
    • Last Year
    • Last two Years
    • Max
    • Daily
    • Weekly
    • Monthly
    Date Close Change Change (%) Open High Low
    Sep 22, 2023 5.18 -0.03 -0.58% 5.21 5.28 5.11
    Sep 21, 2023 5.27 0.04 0.76% 5.23 5.34 5.15
    Sep 20, 2023 5.25 -0.08 -1.50% 5.33 5.47 5.18
    Sep 19, 2023 5.31 -0.04 -0.75% 5.35 5.48 5.27
    Sep 18, 2023 5.36 0.00 0.00% 5.36 5.55 5.31
    Sep 15, 2023 5.30 -0.20 -3.64% 5.50 5.53 5.27
    Sep 14, 2023 5.58 0.05 0.90% 5.53 5.73 5.44
    Sep 13, 2023 5.46 -0.12 -2.15% 5.58 5.81 5.45
    Sep 12, 2023 5.55 -0.13 -2.29% 5.68 5.82 5.53
    Sep 11, 2023 5.87 0.17 2.98% 5.70 5.99 5.68
    Sep 8, 2023 5.79 0.00 0.00% 5.79 5.88 5.76
    Sep 7, 2023 5.88 0.12 2.08% 5.76 5.96 5.70
    Sep 6, 2023 5.80 -0.01 -0.17% 5.81 5.86 5.59
    Sep 5, 2023 5.78 -0.16 -2.69% 5.94 5.98 5.75
    Sep 1, 2023 6.01 0.18 3.09% 5.83 6.12 5.83
    Aug 31, 2023 5.84 -0.11 -1.85% 5.95 6.00 5.80
    Aug 30, 2023 5.94 0.02 0.34% 5.92 5.99 5.85
    Aug 29, 2023 5.94 -0.39 -6.16% 6.33 6.33 5.81
    Aug 28, 2023 6.37 0.48 8.15% 5.89 6.47 5.88
    Aug 25, 2023 5.94 0.09 1.54% 5.85 6.03 5.71

    PDS Biotechnology Corporation Events

    Time (UTC) Country Event
    Monday, November 13, 2023

    Time (UTC)

    13:30

    Country

    US

    Event

    Q3 2023 PDS Biotechnology Corp Earnings Release
    Q3 2023 PDS Biotechnology Corp Earnings Release

    Forecast

    -

    Previous

    -
    View all events
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total revenue 0 0 0 0 0
    Revenue 0
    Total Operating Expense 41.6724 21.4393 14.9024 7.70005 43.0966
    Selling/General/Admin. Expenses, Total 12.2414 10.1848 6.96233 8.91149 15.0205
    Research & Development 29.431 11.2545 7.92445 6.09958 16.0688
    Operating Income -41.6724 -21.4393 -14.9024 -7.70005 -43.0966
    Interest Income (Expense), Net Non-Operating -0.38134 0.00435 0.05501 0.31993 -0.55338
    Other, Net 0 0
    Net Income Before Taxes -42.0538 -21.435 -14.8474 -7.38012 -43.6499
    Net Income After Taxes -40.8549 -16.9185 -14.8474 -6.99861 -40.868
    Net Income Before Extra. Items -40.8549 -16.9185 -14.8474 -6.99861 -40.868
    Net Income -40.8549 -16.9185 -14.8474 -6.99861 -40.868
    Total Adjustments to Net Income
    Income Available to Common Excl. Extra. Items -40.8549 -16.9185 -14.8474 -6.99861 -40.868
    Income Available to Common Incl. Extra. Items -40.8549 -16.9185 -14.8474 -6.99861 -40.868
    Diluted Net Income -40.8549 -16.9185 -14.8474 -6.99861 -40.868
    Diluted Weighted Average Shares 28.5992 25.5971 16.745 4.86808 1.56211
    Diluted EPS Excluding Extraordinary Items -1.42853 -0.66095 -0.88667 -1.43765 -26.1621
    Diluted Normalized EPS -1.42853 -0.66095 -0.85692 -2.41384 -21.1658
    Total Extraordinary Items 0
    Unusual Expense (Income) 0 -7.31102 12.0073
    Depreciation / Amortization 0.01561 0
    Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
    Total revenue 0 0 0 0 0
    Total Operating Expense 12.6962 9.42241 18.8214 7.2792 7.09265
    Selling/General/Admin. Expenses, Total 4.69132 3.57873 2.66627 2.92621 3.33101
    Research & Development 8.00485 5.84369 16.1551 4.35299 3.76165
    Operating Income -12.6962 -9.42241 -18.8214 -7.2792 -7.09265
    Interest Income (Expense), Net Non-Operating -0.24475 -0.23751 -0.14525 0.07455
    Net Income Before Taxes -12.9409 -9.65992 -19.1377 -7.42445 -7.01811
    Net Income After Taxes -11.5349 -9.65992 -19.1377 -7.42445 -5.8192
    Net Income Before Extra. Items -11.5349 -9.65992 -19.1377 -7.42445 -5.8192
    Net Income -11.5349 -9.65992 -19.1377 -7.42445 -5.8192
    Income Available to Common Excl. Extra. Items -11.5349 -9.65992 -19.1377 -7.42445 -5.8192
    Income Available to Common Incl. Extra. Items -11.5349 -9.65992 -19.1377 -7.42445 -5.8192
    Diluted Net Income -11.5349 -9.65992 -19.1377 -7.42445 -5.8192
    Diluted Weighted Average Shares 30.8025 30.428 29.0379 28.4587 28.4516
    Diluted EPS Excluding Extraordinary Items -0.37448 -0.31747 -0.65906 -0.26089 -0.20453
    Dividends per Share - Common Stock Primary Issue 0 0 0 0
    Diluted Normalized EPS -0.37448 -0.31747 -0.65906 -0.26089 -0.20453
    Other, Net -0.31633
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total Current Assets 76.4804 66.8402 30.3372 14.4702 35.6511
    Cash and Short Term Investments 73.8202 65.2426 28.8396 12.1617 34.6455
    Cash & Equivalents 73.8202 65.2426 28.8396 12.1617 34.6455
    Prepaid Expenses 2.66023 1.59757 1.49767 2.30846 1.00559
    Total Assets 77.0079 67.1979 30.8904 14.4913 36.221
    Property/Plant/Equipment, Total - Net 0.52753 0.3577 0.55315 0.02105 0.42695
    Property/Plant/Equipment, Total - Gross 0.64295 0.47303 0.66313 0.11542 0.87862
    Accumulated Depreciation, Total -0.11542 -0.11533 -0.10998 -0.09437 -0.45166
    Other Long Term Assets, Total 0 0.14287
    Total Current Liabilities 9.82104 3.75603 3.27045 2.79355 6.38175
    Accounts Payable 1.21929 1.3094 1.41522 1.19772 0.39945
    Accrued Expenses 8.54514 2.44663 1.85523 1.09764 0.38616
    Notes Payable/Short Term Debt 0 0 0 0 0
    Current Port. of LT Debt/Capital Leases 0.05661 0
    Other Current Liabilities, Total 0 0.49819 5.59614
    Total Liabilities 33.0059 3.98746 3.7608 2.79355 6.38175
    Total Long Term Debt 23.1849 0 0 0 0
    Long Term Debt 23.0208 0 0
    Total Equity 44.002 63.2104 27.1296 11.6977 29.8392
    Common Stock 0.00996 0.00939 0.00735 0.00174 0.01059
    Additional Paid-In Capital 145.55 123.905 70.9073 40.6337 222.645
    Retained Earnings (Accumulated Deficit) -101.558 -60.7036 -43.7851 -28.9377 -192.816
    Total Liabilities & Shareholders’ Equity 77.0079 67.1979 30.8904 14.4913 36.221
    Total Common Shares Outstanding 30.1703 28.4486 22.2616 5.28124 1.5725
    Preferred Stock - Non Redeemable, Net 0
    Other Liabilities, Total 0 0.23143 0.49035 0
    Capital Lease Obligations 0.16401
    Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
    Total Current Assets 67.9734 76.4804 74.4113 55.7426 60.7305
    Cash and Short Term Investments 65.1994 73.8202 71.6424 52.9847 58.8811
    Cash & Equivalents 65.1994 73.8202 71.6424 52.9847 58.8811
    Prepaid Expenses 2.77399 2.66023 2.76891 2.75791 1.84941
    Total Assets 68.4486 77.0079 74.8868 56.0008 61.0388
    Property/Plant/Equipment, Total - Net 0.47526 0.52753 0.47542 0.25819 0.30833
    Total Current Liabilities 4.12954 9.82104 4.84114 4.51592 5.01849
    Accounts Payable 2.07206 1.21929 2.03739 1.87799 2.74571
    Accrued Expenses 2.00537 8.54514 2.74248 2.63793 2.27278
    Notes Payable/Short Term Debt 0 0 0 0 0
    Total Liabilities 27.4377 33.0059 27.8279 4.57557 5.16547
    Total Long Term Debt 23.3081 23.1849 22.9868 0 0
    Other Liabilities, Total 0 0 0.05965 0.14698
    Total Equity 41.0109 44.002 47.0588 51.4252 55.8734
    Common Stock 0.01014 0.00996 0.00939 0.00939 0.00939
    Additional Paid-In Capital 152.219 145.55 129.47 126.412 125.041
    Retained Earnings (Accumulated Deficit) -111.218 -101.558 -82.4207 -74.9963 -69.1771
    Total Liabilities & Shareholders’ Equity 68.4486 77.0079 74.8868 56.0008 61.0388
    Total Common Shares Outstanding 30.7236 30.1703 28.4587 28.4587 28.4509
    Current Port. of LT Debt/Capital Leases 0.05211 0.05661 0.06127
    Long Term Debt 23.1428 23.0208 22.9097
    Capital Lease Obligations 0.16529 0.16401 0.07713
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Net income/Starting Line -40.8549 -16.9185 -14.8474 -6.99861 -40.868
    Cash From Operating Activities -25.7097 -12.4861 -13.1491 -18.0735 -33.1533
    Cash From Operating Activities 0.04908 0.00536 0.01561 0.09841 0.17435
    Non-Cash Items 10.6211 4.35124 0.61297 -6.22017 10.9689
    Cash Interest Paid 0.85222 0 1.05117
    Changes in Working Capital 4.47498 0.07582 1.06967 -4.5716 -3.4285
    Cash From Investing Activities 0 29.3815 0
    Capital Expenditures 0
    Cash From Financing Activities 34.2872 48.8891 29.827 0.75 -20.2688
    Financing Cash Flow Items -0.72029 -0.99
    Issuance (Retirement) of Stock, Net 10.0075 48.8891 29.827 0.75 0.7212
    Issuance (Retirement) of Debt, Net 25 0 -20
    Net Change in Cash 8.57754 36.4031 16.6778 12.058 -53.4221
    Deferred Taxes 0 -0.38151
    Cash Taxes Paid 0
    Other Investing Cash Flow Items, Total 0 29.3815
    Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
    Net income/Starting Line -9.65992 -40.8549 -21.7172 -14.2927 -8.47352
    Cash From Operating Activities -13.1886 -25.7097 -18.1808 -12.2879 -6.36901
    Cash From Operating Activities 0.01411 0.04908 0.0375 0.00009 0.00009
    Non-Cash Items 2.26257 10.6211 4.07542 2.59809 1.18923
    Changes in Working Capital -5.8054 4.47498 -0.57652 -0.59332 0.9152
    Cash From Financing Activities 4.56786 34.2872 24.5806 0.02992 0.00749
    Issuance (Retirement) of Stock, Net 4.58852 10.0075 0.02992 0.02992 0.00749
    Net Change in Cash -8.62078 8.57754 6.39982 -12.2579 -6.36152
    Cash Interest Paid 0.96685 0.85222 0.0625
    Financing Cash Flow Items -0.72029 -0.44933
    Issuance (Retirement) of Debt, Net -0.02067 25 25

    Trading calculator

    Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

    Trade commission
    0
    • 1:1
    Leverage
    1:1
    • 20
    • 100
    • 500
    • 1000
    • 10000
    Investment
    Trade size (Leverage x Investement):
    Open

    Close

    Short Long
    Past performance is not a reliable indicator of future results For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)
    Profit/Loss

    For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

    PDS Biotechnology Corporation Company profile

    PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, human papillomavirus associated malignancies, and cervical cancer. The company is also developing various product candidates, which are in preclinical trials, including PDS0102 T-cell receptor gamma alternate reading frame protein (TARP) for treating prostate and breast cancers; PDS0103 (MUC-1) for ovarian, colorectal, lung, and breast cancers; and PDS0104, which include Tyrosinase-related protein 2 for the treatment of melanoma. In addition, it is developing PDS0201 for treating tuberculosis; PDS0202, an influenza vaccine candidate; and PDS0203, a vaccine for the prevention of COVID-19. The company has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. PDS Biotechnology Corporation was founded in 2005 and is based in Florham Park, New Jersey.
    Industry: Bio Therapeutic Drugs

    25B Vreeland Road
    Suite 300
    FLORHAM PARK
    NEW JERSEY 07932
    US

    Income Statement

    • Annual
    • Quarterly

    News

    EUR/USD tests key support

    EUR/USD is currently testing a key support level after the Federal Reserve indicated a potential extension of higher interest rates.

    14:32, 21 September 2023
    Bank of England building

    BoE leaves rates unchanged, GBP drops further as investors look for more clarity

    The Bank of England has left rates unchanged at 5.25% with a 5-4 vote split after CPI dropped more than expected in August

    11:45, 21 September 2023
    British banknotes and coins photographed directly above. The coins are in a stack, placed on top of the banknotes.

    GBP softer after CPI surprise, JPY focused on any further hints from Ueda

    GBP drops after a softer CPI reading scares investors about the BoE intentions. JPY on the lookout for further policy tweaks from Governor Ueda.

    12:42, 20 September 2023

    How to Trade The Break & Retest

    In this week's instalment, we delve into the Break & Retest pattern—a strategic approach to navigating breakout trades. If you've wrestled with the frustration of false breakouts, incorporating this pattern into your trading toolkit may help you overcome this challenge and put you on the path to becoming a more confident and consistent trader.

    11:59, 20 September 2023

    Cable coils near lows ahead of Fed and BoE rate decisions

    It’s a big week for Cable (GBP/USD) as both the Federal Reserve and the Bank of England are set to make crucial rate decisions.

    14:16, 19 September 2023

    FTSE 100 Technical Outlook - 18 September 2023

    In prior technical outlooks, we highlighted the importance of staying alert in sleepy markets, and last Thursday’s developments on the FTSE 100 serve as a prime illustration of this principle.

    06:55, 19 September 2023
    View of the City of London’s illuminated financial district skyline at dusk

    Market Analysis: FTSE 100 boosted by ECB rate hike end and iron ore rally

    The FTSE 100 rose over 2% on Thursday as the ECB announced no more rate hikes for now.

    13:46, 15 September 2023

    People also watch

    ETH/USD

    1,594.77 Price
    +0.030% 1D Chg, %
    Long position overnight fee -0.0616%
    Short position overnight fee 0.0137%
    Overnight fee time 21:00 (UTC)
    Spread 5.40

    BTC/USD

    26,619.15 Price
    +0.140% 1D Chg, %
    Long position overnight fee -0.0616%
    Short position overnight fee 0.0137%
    Overnight fee time 21:00 (UTC)
    Spread 85.00

    US100

    14,710.90 Price
    +0.190% 1D Chg, %
    Long position overnight fee -0.0262%
    Short position overnight fee 0.0039%
    Overnight fee time 21:00 (UTC)
    Spread 7.0

    Oil - Crude

    90.14 Price
    +0.770% 1D Chg, %
    Long position overnight fee 0.0415%
    Short position overnight fee -0.0634%
    Overnight fee time 21:00 (UTC)
    Spread 0.030

    Still looking for a broker you can trust?

    Join the 555.000+ traders worldwide that chose to trade with Capital.com

    1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading